sellModerate cluster of 3
Rami Elghandour sold $2.4M of ACLX
SEE REMARKS at Arcellx, Inc.. 38,300 shares at an average of $62.02, traded Feb 26, 2025, filed Feb 26, 2025.
Warning score
45Value
$2.4M
38,300 shares
Holdings after
149,186
-20% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +25Trade size$2.4M at market
- +5Share of holdings soldSold 20% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-005794, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 7, 2025 | MOption exercise Common Stock | +70,211 | $0.00 | $0 | 187,486 | Feb 26, 2025 |
| Feb 26, 2025 | SOpen-market sale Common Stock | -6,334 | $61.14 | $387k | 181,152 | Feb 26, 2025 |
| Feb 26, 2025 | SOpen-market sale Common Stock | -21,077 | $61.95 | $1.3M | 160,075 | Feb 26, 2025 |
| Feb 26, 2025 | SOpen-market sale Common Stock | -10,889 | $62.69 | $683k | 149,186 | Feb 26, 2025 |
| Feb 7, 2025 | MOption exercise Restricted Stock Unitderivative | -70,211 | $0.00 | $0 | 0 | Feb 26, 2025 |
Related signals
Other insiders at Arcellx, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Arcellx, Inc. | Rami Elghandour SEE REMARKS | $10M 89,916 shares | -25% | |
| 45Moderate | Arcellx, Inc. | Michelle Gilson CHIEF FINANCIAL OFFICER | $1.3M 11,219 shares | -25% | |
| 39Weak | Arcellx, Inc. | Michelle Gilson CHIEF FINANCIAL OFFICER | $573k 8,384 shares | -16% | |
| 42Moderate | Arcellx, Inc. | Michelle Gilson CHIEF FINANCIAL OFFICER | $785k 11,291 shares | -17% | |
| 10Weak | Arcellx, Inc. | David Charles Lubner director | $450k 6,000 shares | -22% | |
| 29Weak | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $403k 5,882 shares | -20% | |
| 31Weak | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $487k 7,437 shares | -20% | |
| 29Weak | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $393k 6,131 shares | -14% | |
| 20Weak | Arcellx, Inc. | Christopher Heery CHIEF MEDICAL OFFICER | $31k 340 shares | -54% | |
| 30Weak | Arcellx, Inc. | Michelle Gilson CHIEF FINANCIAL OFFICER | $488k 5,364 shares | -39% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.